Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue SEK 1.34bn (+12.8%); operating margin 21.7%; net income SEK 228.0m.
Balance sheet figures not captured from release.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Jul 2026: RaySearch issued a profit warning for Q2 2026, citing several postponed US deals; net sales fell to SEK 272m from SEK 305m. The CEO said the deals were delayed rather than lost.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving RaySearch Laboratories found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Nov 2025: RaySearch initiated an FDA Class 2 recall of RayStation/RayPlan 2024B (v16.0.0) because calculated dose was not correctly invalidated for certain regions of interest; users were given a workaround and a fix was planned for the next version.
Contract delivery, go-lives, terminations and disputes.
Feb 2026: RaySearch announced that The Royal Marsden NHS Foundation Trust is using RayStation for online adaptive radiotherapy on conventional linacs; in Aug 2026 it reported a RayStation order from the University of North Carolina School of Medicine.